Drug Profile

APL 2301

Alternative Names: APL-2301; ASN-1733; MET-102

Latest Information Update: 06 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Asieris Pharmaceuticals
Class Anti-infectives; Antibacterials; Small molecules
Mechanism of Action Bacterial growth inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Acinetobacter infections

Most Recent Events

06 Aug 2026 Phase-I clinical trials in Acinetobacter infections (In volunteers) in Australia (unspecified route) (Asieris Pharmaceuticals pipeline, August 2026)
24 Dec 2023 Pharmacodynamics data from a preclinical trial in Acinetobacter infections released by Asieris Pharmaceuticals
24 Dec 2023 Asieris Pharmaceuticals plans a phase I trial for Acinetobacter infections in Australia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com